CARL ZEISS MEDITEC AG - BR (AFX.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:AFX - DE0005313704 - Common Stock
40.08 EUR
+0.36 (+0.91%)
Taking everything into account, AFX scores 5 out of 10 in our fundamental rating. AFX was compared to 66 industry peers in the Health Care Equipment & Supplies industry. AFX has an average financial health and profitability rating. AFX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year AFX was profitable.
In the past year AFX had a positive cash flow from operations.
AFX had positive earnings in each of the past 5 years.
AFX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of AFX (4.49%) is better than 63.64% of its industry peers.
With a Return On Equity value of 7.51%, AFX perfoms like the industry average, outperforming 56.06% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 4.74%, AFX is in line with its industry, outperforming 42.42% of the companies in the same industry.
AFX had an Average Return On Invested Capital over the past 3 years of 9.30%. This is in line with the industry average of 9.66%.
The last Return On Invested Capital (4.74%) for AFX is well below the 3 year average (9.30%), which needs to be investigated, but indicates that AFX had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.49% | ||
| ROE | 7.51% | ||
| ROIC | 4.74% |
ROA(3y)8.42%
ROA(5y)8.24%
ROE(3y)12.26%
ROE(5y)11.91%
ROIC(3y)9.3%
ROIC(5y)9.86%
1.3 Margins
AFX's Profit Margin of 7.19% is in line compared to the rest of the industry. AFX outperforms 54.55% of its industry peers.
AFX's Profit Margin has declined in the last couple of years.
The Operating Margin of AFX (8.55%) is comparable to the rest of the industry.
AFX's Operating Margin has declined in the last couple of years.
AFX has a Gross Margin of 52.43%. This is comparable to the rest of the industry: AFX outperforms 42.42% of its industry peers.
In the last couple of years the Gross Margin of AFX has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.55% | ||
| PM (TTM) | 7.19% | ||
| GM | 52.43% |
OM growth 3Y-25.26%
OM growth 5Y-12.3%
PM growth 3Y-15.52%
PM growth 5Y-4.6%
GM growth 3Y-3.56%
GM growth 5Y-1.56%
2. Health
2.1 Basic Checks
AFX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, AFX has about the same amount of shares outstanding.
Compared to 5 years ago, AFX has less shares outstanding
Compared to 1 year ago, AFX has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.15 indicates that AFX is not in any danger for bankruptcy at the moment.
AFX's Altman-Z score of 3.15 is fine compared to the rest of the industry. AFX outperforms 65.15% of its industry peers.
The Debt to FCF ratio of AFX is 7.17, which is on the high side as it means it would take AFX, 7.17 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of AFX (7.17) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.27 indicates that AFX is not too dependend on debt financing.
AFX has a Debt to Equity ratio of 0.27. This is comparable to the rest of the industry: AFX outperforms 59.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 7.17 | ||
| Altman-Z | 3.15 |
ROIC/WACC0.7
WACC6.75%
2.3 Liquidity
AFX has a Current Ratio of 2.04. This indicates that AFX is financially healthy and has no problem in meeting its short term obligations.
AFX has a better Current ratio (2.04) than 62.12% of its industry peers.
AFX has a Quick Ratio of 1.17. This is a normal value and indicates that AFX is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.17, AFX perfoms like the industry average, outperforming 51.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.04 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
AFX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.00%.
Measured over the past 5 years, AFX shows a small growth in Earnings Per Share. The EPS has been growing by 2.35% on average per year.
AFX shows a small growth in Revenue. In the last year, the Revenue has grown by 5.50%.
The Revenue has been growing slightly by 7.20% on average over the past years.
EPS 1Y (TTM)-25%
EPS 3Y-8.8%
EPS 5Y2.35%
EPS Q2Q%-15.79%
Revenue 1Y (TTM)5.5%
Revenue growth 3Y7.85%
Revenue growth 5Y7.2%
Sales Q2Q%1.92%
3.2 Future
AFX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.55% yearly.
AFX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.84% yearly.
EPS Next Y-14.52%
EPS Next 2Y1.17%
EPS Next 3Y7.8%
EPS Next 5Y13.55%
Revenue Next Year6.32%
Revenue Next 2Y5.59%
Revenue Next 3Y6.13%
Revenue Next 5Y6.84%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 23.44, AFX is valued on the expensive side.
Based on the Price/Earnings ratio, AFX is valued a bit cheaper than the industry average as 68.18% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of AFX to the average of the S&P500 Index (26.38), we can say AFX is valued inline with the index average.
The Price/Forward Earnings ratio is 19.48, which indicates a rather expensive current valuation of AFX.
The rest of the industry has a similar Price/Forward Earnings ratio as AFX.
When comparing the Price/Forward Earnings ratio of AFX to the average of the S&P500 Index (23.83), we can say AFX is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.44 | ||
| Fwd PE | 19.48 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AFX indicates a somewhat cheap valuation: AFX is cheaper than 68.18% of the companies listed in the same industry.
The rest of the industry has a similar Price/Free Cash Flow ratio as AFX.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 43.21 | ||
| EV/EBITDA | 12.01 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)9.99
EPS Next 2Y1.17%
EPS Next 3Y7.8%
5. Dividend
5.1 Amount
AFX has a Yearly Dividend Yield of 1.38%. Purely for dividend investing, there may be better candidates out there.
AFX's Dividend Yield is a higher than the industry average which is at 1.16.
Compared to the average S&P500 Dividend Yield of 1.87, AFX is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.38% |
5.2 History
The dividend of AFX decreases each year by -1.59%.
Dividend Growth(5Y)-1.59%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
AFX pays out 33.69% of its income as dividend. This is a sustainable payout ratio.
DP33.69%
EPS Next 2Y1.17%
EPS Next 3Y7.8%
FRA:AFX (12/19/2025, 7:00:00 PM)
40.08
+0.36 (+0.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners25.58%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.58B
Revenue(TTM)2.18B
Net Income(TTM)155.89M
Analysts73.64
Price Target55.56 (38.62%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.38% |
Yearly Dividend0.6
Dividend Growth(5Y)-1.59%
DP33.69%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.71%
Min EPS beat(2)-36.67%
Max EPS beat(2)13.25%
EPS beat(4)2
Avg EPS beat(4)-5.53%
Min EPS beat(4)-36.67%
Max EPS beat(4)37.18%
EPS beat(8)6
Avg EPS beat(8)8.89%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)2.29%
Min Revenue beat(2)0.82%
Max Revenue beat(2)3.76%
Revenue beat(4)3
Avg Revenue beat(4)0.58%
Min Revenue beat(4)-2.4%
Max Revenue beat(4)3.76%
Revenue beat(8)5
Avg Revenue beat(8)-0.67%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.25%
EPS NQ rev (1m)-4.88%
EPS NQ rev (3m)-4.88%
EPS NY rev (1m)-0.85%
EPS NY rev (3m)-4.94%
Revenue NQ rev (1m)-0.2%
Revenue NQ rev (3m)-0.2%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.44 | ||
| Fwd PE | 19.48 | ||
| P/S | 1.65 | ||
| P/FCF | 43.21 | ||
| P/OCF | 18.33 | ||
| P/B | 1.73 | ||
| P/tB | 9.24 | ||
| EV/EBITDA | 12.01 |
EPS(TTM)1.71
EY4.27%
EPS(NY)2.06
Fwd EY5.13%
FCF(TTM)0.93
FCFY2.31%
OCF(TTM)2.19
OCFY5.46%
SpS24.26
BVpS23.21
TBVpS4.34
PEG (NY)N/A
PEG (5Y)9.99
Graham Number29.88
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.49% | ||
| ROE | 7.51% | ||
| ROCE | 6.52% | ||
| ROIC | 4.74% | ||
| ROICexc | 4.83% | ||
| ROICexgc | 12.2% | ||
| OM | 8.55% | ||
| PM (TTM) | 7.19% | ||
| GM | 52.43% | ||
| FCFM | 3.82% |
ROA(3y)8.42%
ROA(5y)8.24%
ROE(3y)12.26%
ROE(5y)11.91%
ROIC(3y)9.3%
ROIC(5y)9.86%
ROICexc(3y)9.4%
ROICexc(5y)9.95%
ROICexgc(3y)15.11%
ROICexgc(5y)14.88%
ROCE(3y)12.78%
ROCE(5y)13.55%
ROICexgc growth 3Y-11.32%
ROICexgc growth 5Y-4.98%
ROICexc growth 3Y-28.53%
ROICexc growth 5Y-15.45%
OM growth 3Y-25.26%
OM growth 5Y-12.3%
PM growth 3Y-15.52%
PM growth 5Y-4.6%
GM growth 3Y-3.56%
GM growth 5Y-1.56%
F-Score4
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 7.17 | ||
| Debt/EBITDA | 1.68 | ||
| Cap/Depr | 73.33% | ||
| Cap/Sales | 5.19% | ||
| Interest Coverage | 13.7 | ||
| Cash Conversion | 57.69% | ||
| Profit Quality | 53.21% | ||
| Current Ratio | 2.04 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 3.15 |
F-Score4
WACC6.75%
ROIC/WACC0.7
Cap/Depr(3y)128.62%
Cap/Depr(5y)113.53%
Cap/Sales(3y)5.71%
Cap/Sales(5y)4.9%
Profit Quality(3y)45.51%
Profit Quality(5y)74.23%
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3Y-8.8%
EPS 5Y2.35%
EPS Q2Q%-15.79%
EPS Next Y-14.52%
EPS Next 2Y1.17%
EPS Next 3Y7.8%
EPS Next 5Y13.55%
Revenue 1Y (TTM)5.5%
Revenue growth 3Y7.85%
Revenue growth 5Y7.2%
Sales Q2Q%1.92%
Revenue Next Year6.32%
Revenue Next 2Y5.59%
Revenue Next 3Y6.13%
Revenue Next 5Y6.84%
EBIT growth 1Y-40.66%
EBIT growth 3Y-19.39%
EBIT growth 5Y-5.98%
EBIT Next Year56.91%
EBIT Next 3Y26.03%
EBIT Next 5Y19.93%
FCF growth 1Y-30.57%
FCF growth 3Y-31.55%
FCF growth 5Y-11.27%
OCF growth 1Y-1.41%
OCF growth 3Y-11.98%
OCF growth 5Y2.4%
CARL ZEISS MEDITEC AG - BR / AFX.DE FAQ
What is the fundamental rating for AFX stock?
ChartMill assigns a fundamental rating of 5 / 10 to AFX.DE.
Can you provide the valuation status for CARL ZEISS MEDITEC AG - BR?
ChartMill assigns a valuation rating of 2 / 10 to CARL ZEISS MEDITEC AG - BR (AFX.DE). This can be considered as Overvalued.
Can you provide the profitability details for CARL ZEISS MEDITEC AG - BR?
CARL ZEISS MEDITEC AG - BR (AFX.DE) has a profitability rating of 5 / 10.
What is the valuation of CARL ZEISS MEDITEC AG - BR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CARL ZEISS MEDITEC AG - BR (AFX.DE) is 23.44 and the Price/Book (PB) ratio is 1.73.
What is the financial health of CARL ZEISS MEDITEC AG - BR (AFX.DE) stock?
The financial health rating of CARL ZEISS MEDITEC AG - BR (AFX.DE) is 6 / 10.